New perspectives in the management of Pseudomonas aeruginosa infections

Future Microbiology

Volumn 9, Issue 7, 2014, Pages 917-928

  Savoia, Dianella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

bacteriophages; biofilm; cystic fibrosis; immunotherapy; nanoparticles; Pseudomonas aeruginosa; quorum sensing

Indexed keywords

ANTIBIOTIC AGENT; DENDRIMER; GALLIUM NITRATE; LACTOFERRIN; MONOCLONAL ANTIBODY; PSEUDOMONAS VACCINE; SILVER NANOPARTICLE; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL VIRULENCE; BACTERIOPHAGE; BIOFILM; CELL DENSITY; CELLS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INNATE IMMUNITY; IRON TRANSPORT; MUCOSAL IMMUNITY; NONHUMAN; PHAGOCYTOSIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOMONAS INFECTION; QUORUM SENSING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANIMAL; BIOLOGICAL THERAPY; DRUG EFFECTS; GENETICS; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOLOGICAL THERAPY; HUMANS; IMMUNOTHERAPY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 84906673077     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.42     Document Type: Review

References (111)

1. Ruiz L, Dom'nguez A, Ruiz N, Viñas M. Relationship between clinical and environmental isolates of Pseudomonas aeruginosa in a hospital setting. Arch. Med. Res. 35, 251-257 (2004).
2. Hauser AR, Jain M, Bar-Meir M, McColley SA. Clinical significance of microbial infection and adaptation in cystic fibrosis. Clin. Microbiol. Rev. 24, 29-70 (2011).
3. Martin SJ, Yost RJ. Infectious disease in the critically ill patients. J. Pharm. Pract. 24, 35-43 (2011).
4. Shupp JW, Pavlovich AR, Jeng JC et al. Epidemiology of bloodstream infections in burn-injured patients: a review of the national burn repository. J. Burn Care Res. 31, 521-528 (2010).
5. Williams BJ, Dehnbostel J, Blackwell TS. Pseudomonas aeruginosa: host defence in lung diseases. Respirology 15, 1037-1056 (2010).
6. Cohen TS, Prince A. Cystic fibrosis: a mucosal immunodeficiency syndrome. Nat. Med. 18, 509-519 (2012).
7. Gross J, Welch M. Why is Pseudomonas aeruginosa a common cause of infection in individuals with cystic fibrosis? Future Microbiol. 8, 1-3 (2013).
8. Ciofu O, Hansen CR, Høiby N. Respiratory bacterial infections in cystic fibrosis. Curr. Opin. Pulm. Med. 19, 251-258 (2013).
9. Leone I, Chirillo MG, Raso T, Zucca M, Savoia D. Phenotypic and genotypic characterization of Pseudomonas aeruginosa from cystic fibrosis patients. Eur. J. Clin. Microbiol. Infect. Dis. 27, 1093-1099 (2008).
10. Lambiase A, Raia V, Del Pezzo M et al. Microbiology of airway disease in a cohort of patients with cystic fibrosis. BMC Infect. Dis. 6, 4 (2006).
11. Valenza G, Tappe D, Turnwald D et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 7, 123-127 (2008).
12. Strateva T, Yordanon D. Pseudomonas aeruginosa - a phenomenon of bacterial resistance. J. Med. Microbiol. 58, 1133-1148 (2009).
13. Breidenstein EB, de la Fuente-Nunez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol. 19, 419-426 (2011).
14. Cabot G, Ocampo-Sosa AA, Dominguez MA et al. Genetic markers of widespread extensively drug-resistant Pseudomonas aeruginosa high-risk clones. Antimicrob. Agents Chemother. 56, 6349-6357 (2012).
15. Høiby N, Ciofu O, Bjamsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 5, 1663-1674 (2010).
16. Girard G, Bloemberg GV. Central role of quorum sensing in regulating the production of pathogenicity factors in Pseudomonas aeruginosa. Future Microbiol. 3, 97-106 (2008).
17. Hogardt M, Heesemann J. Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung. Int. J. Med. Microbiol. 300, 557-562 (2010).
18. Hogardt M, Heesemann J. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr. Top. Microbiol. Immunol. 358, 91-118 (2013).
19. Workentine ML, Sibley CD, Glezerson B et al. Phenotypic heterogeneity of Pseudomonas aeruginosa populations in a cystic fibrosis patient. PLoS ONE 8, e60225 (2013).
20. Wareham DW, Curtis MA. A genotypic and phenotypic comparison of type III secretion profiles of Pseudomonas aeruginosa cystic fibrosis and bacteremia isolates. Int. J. Med. Microbiol. 297, 227-234 (2007).
21. Howell HA, Logan LK, Hauser AR. Type III secretion of ExoU is critical during early Pseudomonas aeruginosa pneumonia. MBio 4, e00032-e00113 (2013).
22. Manos J, Hu H, Rose RR et al. Virulence factors expression patterns in Pseudomonas aeruginosa strains from infants with cystic fibrosis. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1583-1592 (2013).
23. Harmer C, Alnassafi K, Hu H et al. Modulation of gene expression by Pseudomonas aeruginosa during chronic infection in the adult CF lung. Microbiology 159, 2354-2363 (2013).
24. Filloux A. Protein secretion systems in Pseudomonas aeruginosa: an essay on diversity, evolution, and function. Front. Microbiol. 2, 155 (2011).
25. Neidig A, Yeung AT, Rosay T et al. TypA is involved in virulence, antimicrobial resistance and biofilm formation in Pseudomonas aeruginosa. BMC Microbiol. 13, 77-86 (2013).
26. Jensen PO, Givskov M, Bjamsholt T et al. The immune system vs Pseudomonas aeruginosa biofilms. FEMS Immunol. Med. Microbiol. 59, 292-305 (2010).
27. Goss CH, Burns J L. Exacerbations in cystic fibrosis 1: epidemiology and pathogenesis. Thorax 62, 360-367 (2007).
28. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl Acad. Sci. USA 103, 8487-8492 (2006).
29. Fothergill JL, Mowat E, Ledson MJ et al. Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations. J. Med. Microbiol. 59, 472-481 (2010).
30. Bjarnsholt T, Høiby N, Donelli G et al. Understanding biofilms - are we there yet? FEMS Immunol. Med. Microbiol. 65, 125-126 (2012).
31. Ciofu O, Mandsberg LF, Wang H, Høiby N. Phenotypes selected during chronic lung infection in cystic fibrosis patients: implications for the treatment of Pseudomonas aeruginosa biofilm infections. FEMS Immunol. Med. Microbiol. 65, 215-225 (2012).
32. Döring G, Flume P, Heijerman H et al. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 11, 461-479 (2012).
33. Høiby N. Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. BMC Med. 9, 32 (2011).
34. Okusanya OO, Bhavnani SM, Hammel J et al. Pharmacokinetic and pharmakodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas infection. Antimicrob. Agents Chemother. 53, 3847-3854 (2009).
35. Trapnell BC, McColley SA, Kissner DG et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection. Am. J. Respir. Crit. Care Med. 185, 171-178 (2012).
36. Hutchinson D, Barclay M, Prescott WA, Brown J. Inhaled aztreonam lysine: an evidence-based review. Expert Opin. Pharmacother. 14, 2115-2124 (2013).
37. Gaspar MC, Couet W, Olivier JC. Pais AA, Sousa JJ. Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1231-1252 (2013).
38. Stockmann C, Sherwin CM, Ampofo K, Spigarelli MG. Development of levofloxacin inhalation solution to treat Pseudomonas aeruginosa in patients with cystic fibrosis. Ther. Adv. Respir. Dis. 8, 13-21 (2014).
39. Hurley M, Càmara M, Smyth AR. Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J. 40, 1014-1023 (2012).
40. Srinivas N, Jetter P, Ueberbacher BJ et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 327, 1010-1013 (2010).
41. Gutierrez M, Choi MH, Tian B et al. Simultaneous inhibition of rhamnolipid and polyhydroxyalkanoic acid synthesis and biofilm formation in Pseudomonas aeruginosa by 2-bromoalkanoic acids: effect of inhibitor alkyl-chain-length. PLoS ONE 8, e73986 (2013).
42. Fothergill JL, Winstanley C, James CE. Novel therapeutic strategies to counter Pseudomonas aeruginosa infections. Expert Rev. Anti Infect. Ther. 10, 219-235 (2012).
43. Sharma G, Rao S, Bansai A et al. Pseudomonas aeruginosa biofilm: potential therapeutic targets. Biologicals 42, 1-7 (2014).
44. Hurley MN, Forrester DI, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst. Rev. 6, CD008037 (2013).
45. Palanisamy NK, Ferina N, Amirulhusni AN et al. Antibiofilm properties of chemically synthesized silver nanoparticles found against Pseudomonas aeruginosa. J. Nanobiotechnol. doi:10.1186/1477-3155-12-2 (2014) (Epub ahead of print).
46. Grishin A, Karyagina AS, Tiganova IG et al. Inhibition of Pseudomonas aeruginosa biofilm formation by LecA-binding polysaccharides. Int. J. Antimicrob. Agents 42, 471-472 (2013).
47. Kolomiets E, Swiderska MA, Kadam RU et al. Glycopeptide dendrimers with high affinity for the fucose-binding lectin LecB from Pseudomonas aeruginosa. ChemMedChem 4, 562-569 (2009).
48. Reymond JL, Bergmann M, Darbre T. Glycopeptide dendrimers as Pseudomonas aeruginosa biofilm inhibitors. Chem. Soc. Rev. 42, 4814-4822 (2013).
49. Kadam RU, Bergmann M, Garg D et al. Structure-based optimization of the terminal tripeptide in glycopeptides dendrimer inhibitors of Pseudomonas aeruginosa biofilms targeting LecA. Chem. Eur. J. 19, 17054-17063 (2013).
50. Lamont IL, Konings AF, Reid DW. Iron acquisition by Pseudomonas aeruginosa in the lungs of patients with cystic fibrosis. BioMetals 22, 53-60 (2009).
51. Reid DW, Carroll V, O'May C, Champion A, Kirov SM. Increased airway iron as a potential factor in the persistence of Pseudomonas aeruginosa infection in cystic fibrosis. Eur. Respir. J. 30, 286-292 (2007).
52. A Pharmacokinetic and Safety Study of IV Gallium Nitrate (Ganite) in Cystic Fibrosis Patients. http://clinicaltrials.gov/show/NCT01093521
53. Halwani M, Yebio B, Suntres ZE, Alipour M, Azghani AO, Omri A. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa. J. Antimicrob. Chemother. 62, 1291-1297 (2008).
54. Bhardwaj AK, Vinothkumar K, Rajpara N. Bacterial quorum sensing inhibitors: attractive alternatives for control of infectious pathogens showing multiple drug resistance. Recent Pat. AntiInfect. Drug Discov. 8, 68-83 (2013).
55. Jakobsen TH, Bjarnsholt T, Jensen PO et al. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors. Future Microbiol. 8, 901-921 (2013).
56. Migiyama Y, Kaneko Y, Yanagihara K et al. Efficacy of AiiM, an N-acylhomoserine lactonase, against Pseudomonas aeruginosa in a mouse model of acute pneumonia. Antimicrob. Agents Chemother. 57, 3653-3658 (2013).
57. Lu Q, Yu J, Yang X et al. Ambroxol interferes with Pseudomonas aeruginosa quorum sensing. Int. J. Antimicrob. Agents 36, 211-215 (2010).
58. Tan SY, Chua SL, Chen Yet al. Identification of five structurally quorum-sensing inhibitors of Pseudomonas aeruginosa from a natural-derivative database. Antimicrob. Agents Chemother. 57, 5629-5641 (2013).
59. O'Loughlin CT, Miller LC, Siryaporn A, Drescher K, Semmelhack MF, Bassler BL. A quorum-sensing inhibitor blocks Pseudomonas aeruginosa virulence and biofilm formation. Proc. Natl Acad. Sci. USA 110, 17981-17986 (2013).
60. Imperi F, Massai F, Pillai CR et al. New life for an old drug: the anthelmintic drug niclosamide inhibits Pseudomonas aeruginosa quorum sensing. Antimicrob. Agents Chemother. 57, 996-1005 (2013).
61. Imperi F, Massai F, Facchini M et al. Repurposing the antimycotic drug flucytosine for suppression of Pseudomonas aeruginosa pathogenicity. Proc. Natl Acad. Sci. USA 110, 7458-7463 (2013).
62. Christiaen SE, Matthijs N, Zhang XH et al. Bacteria that inhibit quorum sensing decrease biofilm formation and virulence in Pseudomonas aeruginosa PAO1. Pathog. Dis. 70, 271-279 (2014).
63. Christiaen SE, Brackman G, Nelis HJ, Coenye T. Isolation and identification of quorum quenching bacteria from environmental samples. J. Microbiol. Methods 87, 213-219 (2011).
64. Verbeken G, De Vos D, Vaneechoutte M et al. European regulatory conundrum of phage therapy. Future Microbiol. 2, 485-491 (2007).
65. Harper DR, Morales S. Bacteriophage therapy: practicability and clinical need meet in the multidrug-resistance era. Future Microbiol. 7, 797-799 (2012).
66. Schmelcher M, Donovan DM, Loessner M. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 7, 1147-1171 (2012).
67. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769-783 (2013).
68. Krylov V, Shaburova O, Krylov S et al. A genetic approach to the development of new therapeutic phages to fight Pseudomonas aeruginosa in wound infections. Viruses 5, 15-53 (2013).
69. Essoh C, Blouin Y, Loukou G et al. The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8, e60575 (2013).
70. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy to guide the choice of therapeutic bacteriophages to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961-5981 (2013).
71. Pastagia M, Schuch R, Fischetti VA et al. Lysins: the arrival of pathogen-directed anti-infectives. J. Med. Microbiol. 62, 1506-1516 (2013).
72. Briers Y, Walmagh M, Lavigne R. Use of bacteriophage endolysin EL188 and outer membrane permeabilizers against Pseudomonas aeruginosa. J. Appl. Microbiol. 110, 778-785 (2011).
73. Rodriguez-Rubio L, Martinez B, Donovan DM et al. Bacteriophage virion-associated peptidoglycan hydrolases: potential new enzybiotics. Crit. Rev. Microbiol. 39, 427-434 (2013).
74. Wu H, Lu H, Huang J et al. EnzyBase: a novel database for enzybiotic studies. BMC Microbiol. 12, 54 (2012).
75. Hojckova K, Stano M, Klucar L. phiBIOTICs: catalogue of therapeutic enzybiotics, relevant research studies and practical applications. BMC Microbiol. 13, 53-58 (2013).
76. Alaxia. www.alaxia-pharma.eu.
77. Xu Y, Szep S, Lu Z. The antioxidant role of thyocianate in the pathogenesis of cystic fibrosis and other inflammation-related diseases. Proc. Natl Acad. Sci. USA 106, 20515-20519 (2009).
78. Georgi E, Le Guellec S, Vecellio L et al. Feasibility sudy of OSCN- and lactoferrin (Meveol) nebulization for cystic fibrosis patients. J. Cyst. Fibros. 10 (Suppl. 1), S18 (2011).
79. Teneback CC, Scanlon TC, Wargo MJ, Bement J, Griswold KE, Leclair LW. Bioengineered lysozyme reduces bacterial burden and inflammation in a murine model of mucoid Pseudomonas aeruginosa lung infection. Antimicrob. Agents Chemother. 57, 5559-5564 (2013).
80. Instinctif Partners. www.collegehill-lifesciences.com.
81. Junkins RD, Shen A, Rosen K, McComick C, Lin TJ. Autophagy enhances bacterial clearance during P. aeruginosa lung infection. PLoS ONE 8, e72263 (2013).
82. Nilsson E, Larsson A, Olesen HV, Wejaker P-E, Kolberg H. Good effect of IgY against Pseudomonas aeruginosa infections in cystic fibrosis patients. Pediatr. Pulmonol. 43, 892-899 (2008).
83. Roux D, Pier GB, Skurnik D. Magic bullets for the 21st century: the reemergence of immunotherapy for multi- and pan-resistant microbes. J. Antimicrob. Chemother. 67, 2785-2787 (2012).
84. Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients. http://clinicaltrials.gov/ ct2/show/ NCT01389700
85. Adawi A, Bisignano C, Genovese T et al. In vitro and in vivo properties of a fully human IgG1 monoclonal antibody that combats multidrug resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 30, 455-464 (2012).
86. DiGiandomenico A, Warrener P, Hamilton M et al. Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Ps1 by phenotypic screening. J. Exp. Med. 209, 1273-1287 (2012).
87. Song Y, Srinivasan R, Lima J et al. PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur. J. Clin. Microbiol. Infect. Dis. 31, 1837-1845 (2012).
88. Baer M, Sawa T, Flynn P et al. An engineered human antibody Fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect. Immun. 77, 1083-1090 (2009).
89. Milla CE, Chmiel JF, Accurso FJ et al. Anti- PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection. Pediatr. Pulmonol. 49, 650-658 (2014).
90. KaloBios. www.kalobios.com
91. Secher T, Fas S, Fauconnier L et al. The anti-Pseudomonas aeruginosa antibody Panobacumab is efficacious on acute pneumonia in neutropenic mice and has additive effects with meropenem. PLoS ONE 8, e 73396 (2013).
92. Lu QL, Rouby JJ, Laterre PF et al. Pharmacokinetics and safety of panobacumab: specific adjunctive immunotherapy in critical patients with nosocomial Pseudomonas aeruginosa O11 pneumonia. J. Antimicrob. Chemother. 66, 1110-1116 (2011).
93. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum. Vaccin. 7, 999-1011 (2011).
94. Worgall S. 40 years on: have we finally got a vaccine for Pseudomonas aeruginosa? Future Microbiol. 7, 1333-1335 (2012).
95. Döring G. Vaccine development for patients with cystic fibrosis. Expert Rev. Vaccines 11, 259-261 (2012).
96. Doring G, Pier GB. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine 26, 1011-1024 (2008).
97. Campodónico VL, Llosa NJ, Grout M et al. Evaluation of flagella and flagellin of Pseudomonas aeruginosa as vaccines. Infect. Immun. 78, 746-755 (2010).
98. Bumann D, Behre C, Behre K et al. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers. Vaccine 28, 707-713 (2010).
99. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst. Rev. 6, CD001399 (2013).
100. Staczek J, Gilleland LB, van der Heyde HC et al. DNA vaccines against chronic lung infections by Pseudomonas aeruginosa. FEMS Immunol. Med. Microbiol. 37, 147-153 (2003).
101. Wu W, Huang J, Duan B et al. Th17- stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med. 186, 420-427 (2012).
102. Sharma A, Krause A, Xu Y et al. Adenovirus-based vaccine with epitopes incorporated in novel fiber sites to induce protective immunity against Pseudomonas aeruginosa. PLoS One 8, e56996 (2013).
103. Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine 24, 849-862 (2006).
104. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. Mol. Ther. 17, 1333-1339 (2009).
105. Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med. 11, S45-S53 (2005).
106. Krause A, Whu WZ, Qui J et al. RGD capsid modification enhances mucosal protective immunity of a non-human primate adenovirus vector expressing Pseudomonas aeruginosa OprF. Clin. Exp. Immunol. 173, 230-241 (2013).
107. Zaman M, Good MF, Toth I. Nanovaccines and their mode of action. Methods 60, 226-231 (2013).
108. Smith DM, Simon JK, Baker JR Jr. Applications of nanotechnology for immunology. Nat. Rev. Immunol. 13, 592-605 (2013).
109. Taranejoo S, Janmaleki M, Rafienia M, Kamali M, Mansouri M. Chitosan microparticles loaded with exotoxin A subunit antigen for intranasal vaccination against Pseudomonas aeruginosa: an in vitro study. Carbohydrate Polymers 83, 1854-1861 (2011).
110. Rodrigues NF, van Tilburg Bernardes E, Rocha RP et al. Bovine serum albumin nanoparticle vaccine reduces lung pathology induced by live Pseudomonas aeruginosa infection in mice. Vaccine 31, 5062-5066 (2013).
111. Polyphor. www.polyphor.com